Array BioPharma to Report Financial Results for the Third Quarter of Fiscal 2010 on May 3, 2010

BOULDER, Colo.--(BUSINESS WIRE)-- Array BioPharma Inc. (Nasdaq: ARRY) will report financial results for the third quarter of fiscal 2010 on Monday, May 3, 2010, and will hold a conference call on Tuesday, May 4, 2010 at 9:00 a.m. Eastern Time to discuss these results. Robert E. Conway, Chief Executive Officer, and Michael Carruthers, Chief Financial Officer, will lead the call.

Conference Call Information

Date:

  Tuesday, May 4, 2010

Time:

9:00 a.m. Eastern Time

Toll-Free:

888-437-9315

Toll:

719-325-2138

Pass Code:

1485835

Webcast:

www.arraybiopharma.com

A replay of the call will be available as a webcast on www.arraybiopharma.com and by phone for one week by dialing toll-free (888) 203-1112 or (719) 457-0820. The access code is 1485835.

About Array BioPharma

Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small-molecule drugs to treat patients afflicted with cancer and inflammatory diseases. Our proprietary drug development pipeline includes clinical candidates that are designed to regulate therapeutically important target proteins and are aimed at significant unmet medical needs. For more information on Array, please go to www.arraybiopharma.com.



CONTACT:

Array BioPharma Inc.
Tricia Haugeto, 303-386-1193
[email protected]

KEYWORDS:   United States  North America  Colorado

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

Genor Biopharma banked $160 million from the likes of Hillhouse and Temasek Holdings to advance its clinical-stage autoimmune and cancer programs.

Going from being the CSO of Bristol Myers Squibb to running one of the biggest cancer research organizations in the world is a major career shift.

Hahn made the commitment in a speech that called on the FDA to learn from the crisis to enact lasting policies that accelerate drug development.